Literature DB >> 1349496

The effect of celiprolol on glomerular filtration rate and renal blood flow in patients with chronic renal impairment and healthy volunteers.

R A Robson1, P G Bridgman, J E Wells, R R Bailey, K L Lynn.   

Abstract

A double-blind, placebo controlled study investigated the effects of celiprolol, 200 mg daily for 7 days, on glomerular filtration rate (GFR) and estimated renal blood flow (ERBF) in eight healthy volunteers and eight patients with chronic renal insufficiency. In healthy volunteers the mean difference in GFR was 4.8 ml min-1 (95% CI -8.2 to 17.7 ml min-1) and the mean difference in ERBF was 49.8 ml min-1 (95% CI -47.5 to 147 ml min-1) after celiprolol. In patients with chronic renal insufficiency the mean difference in GFR was -2.1 ml min-1 (95% CI -64.6 to 65.8 ml min-1). The study had sufficient power to detect a 15% change in GFR for normals and 10% for patients, and for ERBF, changes of 14% and 23% were detectable. Celiprolol at a dose of 200 mg daily for 7 days can be used in patients with chronic renal insufficiency without adversely affecting GFR or ERBF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349496      PMCID: PMC1381339          DOI: 10.1111/j.1365-2125.1992.tb04068.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension.

Authors:  D J Warren; C P Swainson; N Wright
Journal:  Br Med J       Date:  1974-04-27

2.  [Comparative study of the influence of beta-adrenergic stimulants and adrenergic blocking drugs on renal function in normal humans].

Authors:  G Bufano; L Piacentini
Journal:  Minerva Med       Date:  1969-04-04       Impact factor: 4.806

3.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

4.  Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent.

Authors:  Z Glück; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Changes in blood pressure, fluid volumes and glomerular filtration rate during long-term treatment with prizidilol, an antihypertensive drug with combined vasodilatator and beta-adrenoceptor blocking actions.

Authors:  G S Andersen; O J Hartling; H O Hein; A Leth
Journal:  Dan Med Bull       Date:  1985-10

6.  Effects of timolol on blood pressure, systemic hemodynamics, plasma renin activity, and glomerular filtration rate in patients with essential hypertension.

Authors:  E Valvo; L Gammaro; N Tessitore; A Fabris; V Ortalda; V Bedogna; G Maschio
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-03

7.  Comparison of the effects of penbutolol and propranolol on glomerular filtration rate in hypertensive patients with impaired renal function.

Authors:  J van der Meulen; E Reijn; G A Heidendal; P L Oe; A J Donker
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

8.  Mechanism of antihypertensive effect of atenolol in patients with borderline hypertension during short-term treatment. A comprehensive study.

Authors:  Y Imai; K Abe; M Sato; Y Kasai; K Sato; K Omata; S Sasaki; M Nihei; H Sekino; K Yoshinaga
Journal:  Arzneimittelforschung       Date:  1986-05

Review 9.  Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.

Authors:  J G Riddell; R G Shanks; R N Brogden
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

10.  Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.

Authors:  M Solimon; S G Massry; V M Campese
Journal:  Am J Cardiol       Date:  1986-11-26       Impact factor: 2.778

View more
  2 in total

Review 1.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 2.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.